The roles of IL-6, IL-10, and IL-1RA in obesity and insulin resistance in African-Americans.

OBJECTIVE The aim of the study was to investigate the associations between IL-1 receptor antagonist (IL-1RA), IL-6, IL-10, measures of obesity, and insulin resistance in African-Americans. RESEARCH DESIGN AND METHODS Nondiabetic participants (n = 1025) of the Howard University Family Study were investigated for associations between serum IL (IL-1RA, IL-6, IL-10), measures of obesity, and insulin resistance, with adjustment for age and sex. Measures of obesity included body mass index, waist circumference, hip circumference, waist-to-hip ratio, and percent fat mass. Insulin resistance was assessed using the homeostasis model assessment of insulin resistance (HOMA-IR). Data were analyzed with R statistical software using linear regression and likelihood ratio tests. RESULTS IL-1RA and IL-6 were associated with measures of obesity and insulin resistance, explaining 4-12.7% of the variance observed (P values < 0.001). IL-1RA was bimodally distributed and therefore was analyzed based on grouping those with low vs. high IL-1RA levels. High IL-1RA explained up to 20 and 12% of the variance in measures of obesity and HOMA-IR, respectively. Among the IL, only high IL-1RA improved the fit of models regressing HOMA-IR on measures of obesity. In contrast, all measures of obesity improved the fit of models regressing HOMA-IR on IL. IL-10 was not associated with obesity measures or HOMA-IR. CONCLUSIONS High IL-1RA levels and obesity measures are associated with HOMA-IR in this population-based sample of African-Americans. The results suggest that obesity and increased levels of IL-1RA both contribute to the development of insulin resistance.

[1]  C. Rotimi,et al.  Relationships Among Obesity, Inflammation, and Insulin Resistance in African Americans and West Africans , 2010, Obesity.

[2]  E. Boyko,et al.  Insulin Resistance Predicts Mortality in Nondiabetic Individuals in the U.S. , 2010, Diabetes Care.

[3]  G. Taubes.  Insulin resistance. Prosperity's plague. , 2009, Science.

[4]  A. Vaag,et al.  Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes , 2009, Diabetes Care.

[5]  J. Bastard,et al.  The role of interleukins in insulin resistance and type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.

[6]  Eric J. Brunner,et al.  Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes , 2009, Diabetes Care.

[7]  L. Balluz,et al.  Differences in prevalence of obesity among black, white, and Hispanic adults - United States, 2006-2008. , 2009, MMWR. Morbidity and mortality weekly report.

[8]  U. Smith,et al.  Inflamed adipose tissue, insulin resistance and vascular injury , 2008, Diabetes/metabolism research and reviews.

[9]  É. Hajduch,et al.  IL‐1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? , 2006, FEBS letters.

[10]  John N Fain,et al.  Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. , 2006, Vitamins and hormones.

[11]  C. Meier,et al.  Adipose tissue: a regulator of inflammation. , 2005, Best practice & research. Clinical endocrinology & metabolism.

[12]  R. Paschke,et al.  Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[13]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[14]  V. Giusti,et al.  Adipose tissue is a regulated source of interleukin-10. , 2005, Cytokine.

[15]  U. Smith,et al.  Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-α, Overexpressed in Human Fat Cells from Insulin-resistant Subjects* , 2003, Journal of Biological Chemistry.

[16]  A. Golay,et al.  IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? , 2002, The Journal of clinical endocrinology and metabolism.

[17]  Y. Shapira,et al.  Raised interleukin-6 levels in obese patients. , 2000, Obesity research.

[18]  F. Pociot,et al.  Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. , 1993, Cytokine.